{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T13:19:13Z","timestamp":1791551953068,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,13]]},"DOI":"10.7759\/cureus.46946","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T09:41:20Z","timestamp":1697190080000},"source":"Crossref","is-referenced-by-count":6,"title":["Uncovering the Cardiovascular Threat: A Comprehensive Examination of Liver Fibrosis and Subclinical Atherosclerosis in Non-alcoholic Fatty Liver Disease"],"prefix":"10.7759","author":[{"given":"Niketa","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swarupa","family":"Chakole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhushan","family":"Wandile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels S","year":"2022","unstructured":"Pouwels S, Sakran N, Graham Y, et al.. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022, 22:63. 10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X11430859","article-title":"Secondary causes of nonalcoholic fatty liver disease","volume":"5","author":"Kneeman JM","year":"2012","unstructured":"Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2012, 5:199-207. 10.1177\/1756283X11430859","journal-title":"Therap Adv Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2019.09.08","article-title":"Epidemiology of non-alcoholic and alcoholic fatty liver diseases","volume":"5","author":"Mitra S","year":"2020","unstructured":"Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol. 2020, 5:16. 10.21037\/tgh.2019.09.08","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher G","year":"2020","unstructured":"Targher G, Byrne CD, Tilg H. NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. Gut. 2020, 69:1691-1705. 10.1136\/gutjnl-2020-320622","journal-title":"Gut"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng ML","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ, et al.. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023, 29:S32-S42. 10.3350\/cmh.2022.0365","journal-title":"Clin Mol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini E","year":"2010","unstructured":"Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010, 51:679-689. 10.1002\/hep.23280","journal-title":"Hepatology"},{"key":"ref7","article-title":"Non alcoholic fatty liver disease and metabolic syndrome","volume":"13","author":"Paschos P","year":"2009","unstructured":"Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia. 2009, 13:9-19.","journal-title":"Hippokratia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6613827","article-title":"NAFLD, insulin resistance, and diabetes mellitus type 2","volume":"2021","author":"Maru\u0161i\u0107 M","year":"2021","unstructured":"Maru\u0161i\u0107 M, Pai\u0107 M, Knobloch M, Liberati Pr\u0161o AM. NAFLD, insulin resistance, and diabetes mellitus type 2. Can J Gastroenterol Hepatol. 2021, 2021:6613827. 10.1155\/2021\/6613827","journal-title":"Can J Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2014.00037","article-title":"Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy","volume":"3","author":"Zhang QQ","year":"2015","unstructured":"Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment strategy. J Clin Transl Hepatol. 2015, 3:78-84. 10.14218\/JCTH.2014.00037","journal-title":"J Clin Transl Hepatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.942753","article-title":"Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality","volume":"9","author":"Ng CH","year":"2022","unstructured":"Ng CH, Wong ZY, Chew NW, et al.. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med. 2022, 9:942753. 10.3389\/fcvm.2022.942753","journal-title":"Front Cardiovasc Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18105227","article-title":"Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors","volume":"18","author":"Juanola O","year":"2021","unstructured":"Juanola O, Mart\u00ednez-L\u00f3pez S, Franc\u00e9s R, G\u00f3mez-Hurtado I. Non-alcoholic fatty liver disease: metabolic, genetic, epigenetic and environmental risk factors. Int J Environ Res Public Health. 2021, 18:10.3390\/ijerph18105227","journal-title":"Int J Environ Res Public Health"},{"key":"ref12","article-title":"Liver function tests","author":"Lala V","year":"2023","unstructured":"Lala V, Zubair M, Minter DA. Liver function tests. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.25122\/jml-2017-0019","article-title":"Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods","volume":"10","author":"L\u0103p\u0103dat AM","year":"2017","unstructured":"L\u0103p\u0103dat AM, Jianu IR, Ungureanu BS, Florescu LM, Gheonea DI, Sovaila S, Gheonea IA. Non-invasive imaging techniques in assessing non-alcoholic fatty liver disease: a current status of available methods. J Med Life. 2017, 10:19-26.","journal-title":"J Med Life"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Sumida Y","year":"2014","unstructured":"Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014, 20:475-485. 10.3748\/wjg.v20.i2.475","journal-title":"World J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/145754","article-title":"Diagnosis and evaluation of nonalcoholic fatty liver disease","volume":"2012","author":"Obika M","year":"2012","unstructured":"Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012, 2012:145754. 10.1155\/2012\/145754","journal-title":"Exp Diabetes Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.23731","article-title":"Magnetic resonance elastography of liver: technique, analysis, and clinical applications","volume":"37","author":"Venkatesh SK","year":"2013","unstructured":"Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013, 37:544-555. 10.1002\/jmri.23731","journal-title":"J Magn Reson Imaging"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy G","year":"2020","unstructured":"Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun. 2020, 4:478-492. 10.1002\/hep4.1479","journal-title":"Hepatol Commun"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v11.i5.412","article-title":"Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis","volume":"11","author":"Li J","year":"2019","unstructured":"Li J, Zhao YR, Tian Z. Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis. World J Hepatol. 2019, 11:412-420. 10.4254\/wjh.v11.i5.412","journal-title":"World J Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i25.8082","article-title":"Oxidative stress as a crucial factor in liver diseases","volume":"20","author":"Cicho\u017c-Lach H","year":"2014","unstructured":"Cicho\u017c-Lach H, Michalak A. Oxidative stress as a crucial factor in liver diseases. World J Gastroenterol. 2014, 20:8082-8091. 10.3748\/wjg.v20.i25.8082","journal-title":"World J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.112","article-title":"The metabolic basis of nonalcoholic steatohepatitis","volume":"3","author":"Chakravarthy MV","year":"2020","unstructured":"Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab. 2020, 3:e00112. 10.1002\/edm2.112","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R067595","article-title":"The role of ER stress in lipid metabolism and lipotoxicity","volume":"57","author":"Han J","year":"2016","unstructured":"Han J, Kaufman RJ. The role of ER stress in lipid metabolism and lipotoxicity. J Lipid Res. 2016, 57:1329-1338. 10.1194\/jlr.R067595","journal-title":"J Lipid Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1148\/rg.296095512","article-title":"MR imaging of liver fibrosis: current state of the art","volume":"29","author":"Faria SC","year":"2009","unstructured":"Faria SC, Ganesan K, Mwangi I, et al.. MR imaging of liver fibrosis: current state of the art. Radiographics. 2009, 29:1615-1635. 10.1148\/rg.296095512","journal-title":"Radiographics"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi Y","year":"2014","unstructured":"Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. World J Gastroenterol. 2014, 20:15539-15548. 10.3748\/wjg.v20.i42.15539","journal-title":"World J Gastroenterol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23478","article-title":"Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis","volume":"51","author":"Garcia-Tsao G","year":"2010","unstructured":"Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: in search of a pathophysiological classification of cirrhosis. Hepatology. 2010, 51:1445-1449. 10.1002\/hep.23478","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.21037\/tgh.2020.02.21","article-title":"Fibrosis and hepatic regeneration mechanism","volume":"7","author":"Zu\u00f1iga-Aguilar E","year":"2022","unstructured":"Zu\u00f1iga-Aguilar E, Ram\u00edrez-Fern\u00e1ndez O. Fibrosis and hepatic regeneration mechanism. Transl Gastroenterol Hepatol. 2022, 7:9. 10.21037\/tgh.2020.02.21","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100067","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel K","year":"2020","unstructured":"Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020, 2:100067. 10.1016\/j.jhepr.2020.100067","journal-title":"JHEP Rep"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.14366\/usg.14003","article-title":"Principles and clinical application of ultrasound elastography for diffuse liver disease","volume":"33","author":"Jeong WK","year":"2014","unstructured":"Jeong WK, Lim HK, Lee HK, Jo JM, Kim Y. Principles and clinical application of ultrasound elastography for diffuse liver disease. Ultrasonography. 2014, 33:149-160. 10.14366\/usg.14003","journal-title":"Ultrasonography"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s13679-019-00345-1","article-title":"Nonalcoholic fatty liver disease and obesity treatment","volume":"8","author":"Brunner KT","year":"2019","unstructured":"Brunner KT, Henneberg CJ, Wilechansky RM, Long MT. Nonalcoholic fatty liver disease and obesity treatment. Curr Obes Rep. 2019, 8:220-228. 10.1007\/s13679-019-00345-1","journal-title":"Curr Obes Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00055","article-title":"Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail","volume":"9","author":"Sharma M","year":"2021","unstructured":"Sharma M, Premkumar M, Kulkarni AV, Kumar P, Reddy DN, Rao NP. Drugs for non-alcoholic steatohepatitis (NASH): quest for the holy grail. J Clin Transl Hepatol. 2021, 9:40-50. 10.14218\/JCTH.2020.00055","journal-title":"J Clin Transl Hepatol"},{"key":"ref30","article-title":"Comorbidities and nonalcoholic fatty liver disease: the chicken, the egg, or both?","volume":"36","author":"Glass LM","year":"2019","unstructured":"Glass LM, Hunt CM, Fuchs M, Su GL. Comorbidities and nonalcoholic fatty liver disease: the chicken, the egg, or both?. Fed Pract. 2019, 36:64-71.","journal-title":"Fed Pract"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13620","article-title":"Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis","volume":"43","author":"Noureddin M","year":"2016","unstructured":"Noureddin M, Anstee QM, Loomba R. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2016, 43:1109-1123. 10.1111\/apt.13620","journal-title":"Aliment Pharmacol Ther"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i18.5442","article-title":"Cirrhosis and its complications: evidence based treatment","volume":"20","author":"Nusrat S","year":"2014","unstructured":"Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014, 20:5442-5460. 10.3748\/wjg.v20.i18.5442","journal-title":"World J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby P","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, et al.. Atherosclerosis. Nat Rev Dis Primers. 2019, 5:56. 10.1038\/s41572-019-0106-z","journal-title":"Nat Rev Dis Primers"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-117","article-title":"Immunity, atherosclerosis and cardiovascular disease","volume":"11","author":"Frosteg\u00e5rd J","year":"2013","unstructured":"Frosteg\u00e5rd J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013, 11:117. 10.1186\/1741-7015-11-117","journal-title":"BMC Med"},{"key":"ref35","article-title":"Atherosclerosis: process, indicators, risk factors and new hopes","volume":"5","author":"Rafieian-Kopaei M","year":"2014","unstructured":"Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med. 2014, 5:927-946.","journal-title":"Int J Prev Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1055\/a-1930-6658","article-title":"Shared mechanisms between cardiovascular disease and NAFLD","volume":"42","author":"Huang DQ","year":"2022","unstructured":"Huang DQ, Downes M, Evans RM, Witztum JL, Glass CK, Loomba R. Shared mechanisms between cardiovascular disease and NAFLD. Semin Liver Dis. 2022, 42:455-464. 10.1055\/a-1930-6658","journal-title":"Semin Liver Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i37.13306","article-title":"Nonalcoholic fatty liver disease and vascular disease: state-of-the-art","volume":"20","author":"Fargion S","year":"2014","unstructured":"Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol. 2014, 20:13306-13324. 10.3748\/wjg.v20.i37.13306","journal-title":"World J Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2018.33.1.33","article-title":"Association of adipokines with development and progression of nonalcoholic fatty liver disease","volume":"33","author":"Boutari C","year":"2018","unstructured":"Boutari C, Perakakis N, Mantzoros CS. Association of adipokines with development and progression of nonalcoholic fatty liver disease. Endocrinol Metab (Seoul). 2018, 33:33-43. 10.3803\/EnM.2018.33.1.33","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-022-01028-4","article-title":"Management of dyslipidemia in patients with non-alcoholic fatty liver disease","volume":"24","author":"Martin A","year":"2022","unstructured":"Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of dyslipidemia in patients with non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2022, 24:533-546. 10.1007\/s11883-022-01028-4","journal-title":"Curr Atheroscler Rep"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2019.00028","article-title":"Pathogenesis of insulin resistance and atherogenic dyslipidemia in nonalcoholic fatty liver disease","volume":"7","author":"Akhtar DH","year":"2019","unstructured":"Akhtar DH, Iqbal U, Vazquez-Montesino LM, Dennis BB, Ahmed A. Pathogenesis of insulin resistance and atherogenic dyslipidemia in nonalcoholic fatty liver disease. J Clin Transl Hepatol. 2019, 7:362-370. 10.14218\/JCTH.2019.00028","journal-title":"J Clin Transl Hepatol"},{"key":"ref41","article-title":"Nonalcoholic steatohepatitis (NASH)","author":"Sharma B","year":"2023","unstructured":"Sharma B, John S. Nonalcoholic steatohepatitis (NASH). StatPearls Publishing, Treasure Island; 2023."},{"key":"ref42","article-title":"Imaging atherosclerosis by carotid Intima-media thickness in vivo: how to, where and in whom?","volume":"7","author":"Onut R","year":"2012","unstructured":"Onut R, Balanescu AP, Constantinescu D, Calmac L, Marinescu M, Dorobantu PM. Imaging atherosclerosis by carotid Intima-media thickness in vivo: how to, where and in whom?. Maedica (Bucur). 2012, 7:153-162.","journal-title":"Maedica (Bucur)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1590\/0100-3984.2015.0235","article-title":"Coronary artery calcium score: current status","volume":"50","author":"Neves PO","year":"2017","unstructured":"Neves PO, Andrade J, Mon\u00e7\u00e3o H. Coronary artery calcium score: current status. Radiol Bras. 2017, 50:182-189. 10.1590\/0100-3984.2015.0235","journal-title":"Radiol Bras"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00471.2010","article-title":"Assessment of flow-mediated dilation in humans: a methodological and physiological guideline","volume":"300","author":"Thijssen DH","year":"2011","unstructured":"Thijssen DH, Black MA, Pyke KE, et al.. Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011, 300:H2-H12. 10.1152\/ajpheart.00471.2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083850","article-title":"Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches","volume":"22","author":"Medina-Leyte DJ","year":"2021","unstructured":"Medina-Leyte DJ, Zepeda-Garc\u00eda O, Dom\u00ednguez-P\u00e9rez M, Gonz\u00e1lez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021, 22:10.3390\/ijms22083850","journal-title":"Int J Mol Sci"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.21037\/cdt.2015.11.07","article-title":"Noninvasive imaging modalities to visualize atherosclerotic plaques","volume":"6","author":"Shishikura D","year":"2016","unstructured":"Shishikura D. Noninvasive imaging modalities to visualize atherosclerotic plaques. Cardiovasc Diagn Ther. 2016, 6:340-353. 10.21037\/cdt.2015.11.07","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001850","article-title":"Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis","volume":"8","author":"Wong MY","year":"2021","unstructured":"Wong MY, Yap JJ, Sultana R, Cheah M, Goh GB, Yeo KK. Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. Open Heart. 2021, 8:10.1136\/openhrt-2021-001850","journal-title":"Open Heart"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.01.023","article-title":"New insights into NAFLD and subclinical coronary atherosclerosis","volume":"68","author":"VanWagner LB","year":"2018","unstructured":"VanWagner LB. New insights into NAFLD and subclinical coronary atherosclerosis. J Hepatol. 2018, 68:890-892. 10.1016\/j.jhep.2018.01.023","journal-title":"J Hepatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.280","article-title":"Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management","volume":"15","author":"Garcia-Compean D","year":"2009","unstructured":"Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009, 15:280-288. 10.3748\/wjg.15.280","journal-title":"World J Gastroenterol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms15046184","article-title":"Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease","volume":"15","author":"Jung UJ","year":"2014","unstructured":"Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014, 15:6184-6223. 10.3390\/ijms15046184","journal-title":"Int J Mol Sci"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S275898","article-title":"Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications","volume":"13","author":"Wondmkun YT","year":"2020","unstructured":"Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: associations and therapeutic implications. Diabetes Metab Syndr Obes. 2020, 13:3611-3616. 10.2147\/DMSO.S275898","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in obesity: mechanisms and potential targets","volume":"5","author":"Klop B","year":"2013","unstructured":"Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: mechanisms and potential targets. Nutrients. 2013, 5:1218-1240. 10.3390\/nu5041218","journal-title":"Nutrients"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58050641","article-title":"Chronic inflammation-a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue","volume":"58","author":"Petrescu M","year":"2022","unstructured":"Petrescu M, Vlaicu SI, Cium\u0103rnean L, et al.. Chronic inflammation-a link between nonalcoholic fatty liver disease (NAFLD) and dysfunctional adipose tissue. Medicina (Kaunas). 2022, 58:10.3390\/medicina58050641","journal-title":"Medicina (Kaunas)"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c200021","article-title":"Oxidative stress and redox signaling in the pathophysiology of liver diseases","volume":"12","author":"Mooli RG","year":"2022","unstructured":"Mooli RG, Mukhi D, Ramakrishnan SK. Oxidative stress and redox signaling in the pathophysiology of liver diseases. Compr Physiol. 2022, 12:3167-3192. 10.1002\/cphy.c200021","journal-title":"Compr Physiol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16173104","article-title":"Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications","volume":"16","author":"Tana C","year":"2019","unstructured":"Tana C, Ballestri S, Ricci F, et al.. Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications. Int J Environ Res Public Health. 2019, 16:10.3390\/ijerph16173104","journal-title":"Int J Environ Res Public Health"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17617","article-title":"Systematic review and meta-analysis: association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease","volume":"58","author":"Jamalinia M","year":"2023","unstructured":"Jamalinia M, Zare F, Lankarani KB. Systematic review and meta-analysis: association between liver fibrosis and subclinical atherosclerosis in nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2023, 58:384-394. 10.1111\/apt.17617","journal-title":"Aliment Pharmacol Ther"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2013.0085","article-title":"The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis","volume":"110","author":"Wiegand J","year":"2013","unstructured":"Wiegand J, Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int. 2013, 110:85-91. 10.3238\/arztebl.2013.0085","journal-title":"Dtsch Arztebl Int"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i16.2041","article-title":"Physical activity as a treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Whitsett M","year":"2015","unstructured":"Whitsett M, VanWagner LB. Physical activity as a treatment of non-alcoholic fatty liver disease: a systematic review. World J Hepatol. 2015, 7:2041-2052. 10.4254\/wjh.v7.i16.2041","journal-title":"World J Hepatol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-017-0584-7","article-title":"Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects","volume":"19","author":"Vargas JI","year":"2017","unstructured":"Vargas JI, Arrese M, Shah VH, Arab JP. Use of statins in patients with chronic liver disease and cirrhosis: current views and prospects. Curr Gastroenterol Rep. 2017, 19:43. 10.1007\/s11894-017-0584-7","journal-title":"Curr Gastroenterol Rep"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00796-x","article-title":"Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach","volume":"20","author":"Brennan PN","year":"2023","unstructured":"Brennan PN, Elsharkawy AM, Kendall TJ, Loomba R, Mann DA, Fallowfield JA. Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. Nat Rev Gastroenterol Hepatol. 2023, 20:679-688. 10.1038\/s41575-023-00796-x","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101155","article-title":"A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health","volume":"10","author":"Moolla A","year":"2019","unstructured":"Moolla A, Motohashi K, Marjot T, et al.. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Frontline Gastroenterol. 2019, 10:337-346. 10.1136\/flgastro-2018-101155","journal-title":"Frontline Gastroenterol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2018.12.016","article-title":"Lifestyle interventions for non-alcoholic fatty liver disease","volume":"26","author":"Ahmed IA","year":"2019","unstructured":"Ahmed IA, Mikail MA, Mustafa MR, Ibrahim M, Othman R. Lifestyle interventions for non-alcoholic fatty liver disease. Saudi J Biol Sci. 2019, 26:1519-1524. 10.1016\/j.sjbs.2018.12.016","journal-title":"Saudi J Biol Sci"},{"key":"ref63","article-title":"Relationship between diet and non-alcoholic fatty liver disease: a review article","volume":"46","author":"Mirmiran P","year":"2017","unstructured":"Mirmiran P, Amirhamidi Z, Ejtahed HS, Bahadoran Z, Azizi F. Relationship between diet and non-alcoholic fatty liver disease: a review article. Iran J Public Health. 2017, 46:1007-1017.","journal-title":"Iran J Public Health"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/ijo.2014.82","article-title":"What is the role of portion control in weight management?","volume":"38 Suppl 1","author":"Rolls BJ","year":"2014","unstructured":"Rolls BJ. What is the role of portion control in weight management?. Int J Obes (Lond). 2014, 38 Suppl 1:S1-S8. 10.1038\/ijo.2014.82","journal-title":"Int J Obes (Lond)"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.84.s1.03","article-title":"The essential role of exercise in the management of type 2 diabetes","volume":"84","author":"Kirwan JP","year":"2017","unstructured":"Kirwan JP, Sacks J, Nieuwoudt S. The essential role of exercise in the management of type 2 diabetes. Cleve Clin J Med. 2017, 84:S15-S21. 10.3949\/ccjm.84.s1.03","journal-title":"Cleve Clin J Med"},{"key":"ref66","article-title":"Alcoholic liver disease: pathogenesis and current management","volume":"38","author":"Osna NA","year":"2017","unstructured":"Osna NA, Donohue TM Jr, Kharbanda KK. Alcoholic liver disease: pathogenesis and current management. Alcohol Res. 2017, 38:147-161.","journal-title":"Alcohol Res"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2020.02.47","article-title":"Cardiovascular risk of smoking and benefits of smoking cessation","volume":"12","author":"Gallucci G","year":"2020","unstructured":"Gallucci G, Tartarone A, Lerose R, Lalinga AV, Capobianco AM. Cardiovascular risk of smoking and benefits of smoking cessation. J Thorac Dis. 2020, 12:3866-3876. 10.21037\/jtd.2020.02.47","journal-title":"J Thorac Dis"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1055\/s-0035-1562951","article-title":"Pharmacotherapy for nonalcoholic fatty liver disease","volume":"35","author":"Gawrieh S","year":"2015","unstructured":"Gawrieh S, Chalasani N. Pharmacotherapy for nonalcoholic fatty liver disease. Semin Liver Dis. 2015, 35:338-348. 10.1055\/s-0035-1562951","journal-title":"Semin Liver Dis"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00026","article-title":"Hepatic antifibrotic pharmacotherapy: are we approaching success?","volume":"8","author":"Chang Y","year":"2020","unstructured":"Chang Y, Li H. Hepatic antifibrotic pharmacotherapy: are we approaching success?. J Clin Transl Hepatol. 2020, 8:222-229. 10.14218\/JCTH.2020.00026","journal-title":"J Clin Transl Hepatol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1241","article-title":"Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality","volume":"2","author":"Shahab O","year":"2018","unstructured":"Shahab O, Biswas R, Paik J, Bush H, Golabi P, Younossi ZM. Among patients with NAFLD, treatment of dyslipidemia does not reduce cardiovascular mortality. Hepatol Commun. 2018, 2:1227-1234. 10.1002\/hep4.1241","journal-title":"Hepatol Commun"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100322","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque SM","year":"2021","unstructured":"Francque SM, Marchesini G, Kautz A, et al.. Non-alcoholic fatty liver disease: a patient guideline. JHEP Rep. 2021, 3:100322. 10.1016\/j.jhepr.2021.100322","journal-title":"JHEP Rep"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0336","article-title":"Screening strategy for non-alcoholic fatty liver disease","volume":"29","author":"Zhang S","year":"2023","unstructured":"Zhang S, Mak LY, Yuen MF, Seto WK. Screening strategy for non-alcoholic fatty liver disease. Clin Mol Hepatol. 2023, 29:S103-S122. 10.3350\/cmh.2022.0336","journal-title":"Clin Mol Hepatol"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.2147\/JHL.S69188","article-title":"Public health policies to encourage healthy eating habits: recent perspectives","volume":"7","author":"Gorski MT","year":"2015","unstructured":"Gorski MT, Roberto CA. Public health policies to encourage healthy eating habits: recent perspectives. J Healthc Leadersh. 2015, 7:81-90. 10.2147\/JHL.S69188","journal-title":"J Healthc Leadersh"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.4103\/0970-0218.94009","article-title":"Health promotion: an effective tool for global health","volume":"37","author":"Kumar S","year":"2012","unstructured":"Kumar S, Preetha G. Health promotion: an effective tool for global health. Indian J Community Med. 2012, 37:5-12. 10.4103\/0970-0218.94009","journal-title":"Indian J Community Med"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman SL","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018, 24:908-922. 10.1038\/s41591-018-0104-9","journal-title":"Nat Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/194007-uncovering-the-cardiovascular-threat-a-comprehensive-examination-of-liver-fibrosis-and-subclinical-atherosclerosis-in-non-alcoholic-fatty-liver-disease","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:14Z","timestamp":1707509234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/194007-uncovering-the-cardiovascular-threat-a-comprehensive-examination-of-liver-fibrosis-and-subclinical-atherosclerosis-in-non-alcoholic-fatty-liver-disease"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":75,"URL":"https:\/\/doi.org\/10.7759\/cureus.46946","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,13]]}}}